The team is led by Hugh Young Rienhoff, Jr., a physician with 25 years of experience in the field of biotechnology. The operational team provides broad oversight of clinical trials, non-clinical studies and manufacturing across the globe. Their industry experience in settings varying from biotechnology to large pharma, brings significant breadth and depth of knowledge of all aspects of discovery, medicinal chemistry, quality and clinical development.
Imago’s business model allows the team to leverage their drug development experience, which includes all aspects of clinical trial conduct in more than 25 countries in multiple disease areas, notably hematology and oncology, with the utilization of vendors and consultants to enhance and accelerate operations. The team has a strong focus on working collaboratively with clinical investigators and scientists to continuously build a stronger scientific foundation for patient studies.